Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Докторантска мрежа2016–2020

GlySign · Exploitation of Glycosylation Signatures for Precision Medicine

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2016-10-01 → 2020-09-30
Финансиране от ЕС
1 552 846 €
Участници
7
Схема
MSCA-ITN-EID

Линиите свързват координатора с партньорите.

Накратко на български

Захаридните вериги (гликани), прикрепени към протеините, се променят при заболявания като рак на простатата и диабет. Анализът на тези промени помага за по-точна диагностика и проследяване на развитието на болестите при отделните пациенти.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Exploitation of Glycosylation Signatures for Precision Medicine

During the progression of many chronic diseases including various inflammatory conditions and cancer complex, distinctive changes occur in the carbohydrates (glycans) that are attached to various proteins. These changes can be observed when measuring the glycomic profiles or – Glycan Signatures – of human glycoproteins by using appropriate analytical platforms. Within the GlySign research and training network a group of young researchers engaged in developing disease glycomic markers together with the suitable analytical technology for clinical translation in the context of Precision Medicine (PM). Glycan signatures have great potential for adding useful diagnostic and prognostic information in PM. However, advancement of this field is slow because (a) glycans have immense structural complexity resulting in major technical challenges for their analysis and (b) there is a lack of experts with required glycoanalytical skills. GlySign addressed this gap by training six early stage researchers (ESRs) within an innovative training-by-research programme with high industrial-academic mobility thereby contributing to the translation of novel glycomics-based diagnostic tools and markers into clinical practice. This was achieved by developing a range of selective and sensitive glycomics technologies for the analysis of samples from patients and healthy controls in close collaboration between industry and academia as well as clinicians. The training focused on clinical glycomics applied to different model diseases assessing changes in the glycosylation of circulating proteins specific to disease progression or subtype: auto- and alloimmune diseases, including rheumatoid arthritis, and diabetes and prostate cancer. With its strong industrial and translational focus, GlySign filled a gap in the healthcare market by contributing to the development of new in-vitro diagnostic platforms for clinical exploitation of glycomic biomarkers for PM. More information on the project and scientists in charge as well as descriptions of individual ESR projects can be found on: www.glysign.eu.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

GlySign is a research training network for the translation of glycomic clinical biomarkers for Precision Medicine (PM). Complex, distinctive changes occur in the glycomics profiles or - Glycan Signatures - of human glycoproteins during progression of many chronic diseases including cancer and inflammatory conditions. The three beneficiaries of the GlySign Consortium have been instrumental in contributing to knowledge in this field through development of glycomics technology and discovery of clinically important novel glycan biomarkers in a variety of diseases. Glycan signatures have great potential for adding useful diagnostic and prognostic information in PM. However, advancement of this field is slow because (a) glycans have immense structural complexity resulting in major technical challenges for their analysis and (b) there is a lack of experts with required glycoanalytical skills. GlySign will address this gap by training six young scientists within an innovative training-by-research programme with high industrial-academic mobility to eventually push forward the translation of novel glycomics-based diagnostic tools into clinical practice. This will be achieved by further developing a range of selective and sensitive glycomics technologies for the analysis of samples from patients and healthy controls in close collaboration between industry/academia as well as clinical chemists and clinicians who will be the end users of GlySign’s final products. To this end, we will focus the training on clinical glycomics applied to four model diseases implicating changes in the glycosylation of circulating proteins specific to disease progression or subtype, i.e. diabetes, prostate cancer, fetal and neonatal alloimmune thrombocytopenia and rheumatoid arthritis. Due to its strong industrial and translational focus, GlySign will, moreover, fill a current gap in the market by establishing new in vitro diagnostic platforms for clinical exploitation of glycomic biomarkers for PM.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз